216 related articles for article (PubMed ID: 7486922)
1. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses.
Lowe DM; Alderton WK; Ellis MR; Parmar V; Miller WH; Roberts GB; Fyfe JA; Gaillard R; Ertl P; Snowden W
Antimicrob Agents Chemother; 1995 Aug; 39(8):1802-8. PubMed ID: 7486922
[TBL] [Abstract][Full Text] [Related]
2. Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus.
Ono N; Iwayama S; Suzuki K; Sekiyama T; Nakazawa H; Tsuji T; Okunishi M; Daikoku T; Nishiyama Y
Antimicrob Agents Chemother; 1998 Aug; 42(8):2095-102. PubMed ID: 9687413
[TBL] [Abstract][Full Text] [Related]
3. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Dec; 42(12):3285-9. PubMed ID: 9835529
[TBL] [Abstract][Full Text] [Related]
4. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.
Earnshaw DL; Bacon TH; Darlison SJ; Edmonds K; Perkins RM; Vere Hodge RA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2747-57. PubMed ID: 1336346
[TBL] [Abstract][Full Text] [Related]
5. Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine.
Ng TI; Shi Y; Huffaker HJ; Kati W; Liu Y; Chen CM; Lin Z; Maring C; Kohlbrenner WE; Molla A
Antimicrob Agents Chemother; 2001 Jun; 45(6):1629-36. PubMed ID: 11353604
[TBL] [Abstract][Full Text] [Related]
6. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate.
Abele G; Eriksson B; Harmenberg J; Wahren B
Antimicrob Agents Chemother; 1988 Aug; 32(8):1137-42. PubMed ID: 2847643
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture.
Abele G; Karlström A; Harmenberg J; Shigeta S; Larsson A; Lindborg B; Wahren B
Antimicrob Agents Chemother; 1987 Jan; 31(1):76-80. PubMed ID: 3032092
[TBL] [Abstract][Full Text] [Related]
9. Testing the sensitivities of noncognate inhibitors to varicella zoster virus thymidine kinase: implications for postherpetic neuralgia therapy with existing agents.
Yang L; Mo X; Yang H; Dai H; Tan F
J Mol Model; 2014 Jul; 20(7):2321. PubMed ID: 24961898
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of herpes simplex virus type 1 DNA polymerase by [1R(1 alpha,2 beta,3 alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine.
Terry BJ; Cianci CW; Hagen ME
Mol Pharmacol; 1991 Oct; 40(4):591-6. PubMed ID: 1656194
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
Manikowski A; Verri A; Lossani A; Gebhardt BM; Gambino J; Focher F; Spadari S; Wright GE
J Med Chem; 2005 Jun; 48(11):3919-29. PubMed ID: 15916444
[TBL] [Abstract][Full Text] [Related]
12. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.
Koyano S; Suzutani T; Yoshida I; Azuma M
Antimicrob Agents Chemother; 1996 Apr; 40(4):920-3. PubMed ID: 8849252
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses.
Sekiyama T; Hatsuya S; Tanaka Y; Uchiyama M; Ono N; Iwayama S; Oikawa M; Suzuki K; Okunishi M; Tsuji T
J Med Chem; 1998 Apr; 41(8):1284-98. PubMed ID: 9548818
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Suzuki M; Okuda T; Shiraki K
Antiviral Res; 2006 Nov; 72(2):157-61. PubMed ID: 16797734
[TBL] [Abstract][Full Text] [Related]
15. Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT-lipid-PFA on human herpesvirus-6B infected cells.
Yao K; Hoest C; Rashti F; Schott TC; Jacobson S
J Clin Virol; 2009 Sep; 46(1):10-4. PubMed ID: 19524486
[TBL] [Abstract][Full Text] [Related]
16. Activation and antiviral effect of acyclovir in cells infected with a varicella-like simian virus.
Fyfe JA; Biron KK; McKee SA; Kelly CM; Elion GB; Soike KF
Am J Med; 1982 Jul; 73(1A):58-61. PubMed ID: 6285734
[TBL] [Abstract][Full Text] [Related]
17. Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG.
Terry BJ; Mazina KE; Tuomari AV; Haffey ML; Hagen M; Feldman A; Slusarchyk WA; Young MG; Zahler R; Field AK
Antiviral Res; 1988 Dec; 10(4-5):235-51. PubMed ID: 2852486
[TBL] [Abstract][Full Text] [Related]
18. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of the 3'-amino derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
De Clercq E; Descamps J; Balzarini J; Fukui T; Allaudeen HS
Biochem J; 1983 May; 211(2):439-45. PubMed ID: 6307280
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and mode of action of (R)-9-(3,4-dihydroxybutyl)guanine in herpes simplex virus-infected vero cells.
Stenberg K; Larsson A; Datema R
J Biol Chem; 1986 Feb; 261(5):2134-9. PubMed ID: 2418021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
